COST ANALYSIS OF PATIENTS WITH MULTIPLE SCLEROSIS NEWLY INITIATING SUBCUTANEOUS INTERFERON β-1A VERSUS ORAL DISEASE-MODIFYING DRUGS

被引：0
|
作者：
Kozma, C. M. [1 ]
Munschauer, F. E. [2 ]
Phillips, A. L. [2 ]
机构：
[1] CK Consulting Associates LLC, St Helena Isl, SC USA
[2] EMD Serono Inc, Rockland, MA USA
来源：
VALUE IN HEALTH | 2016年 / 19卷 / 03期
关键词：
D O I：
10.1016/j.jval.2016.03.220
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PND59
引用
收藏
页码：A69 / A69
页数：1
相关论文
共 50 条
  • [1] Real-World Assessment of Relapse Rates in Patients with Multiple Sclerosis Newly Initiating Subcutaneous Interferon β-1a vs Oral Disease-Modifying Drugs
    Kozma, Chris
    Munschauer, Frederick
    Phillips, Amy
    [J]. NEUROLOGY, 2016, 86
  • [2] Relapse in Patients with Multiple Sclerosis Newly Initiating scIFNβ1a Compared with Oral Disease-Modifying Drugs: A Real-World Assessment
    Bowen, James
    Kozma, Chris
    Grosso, Megan
    Phillips, Amy
    [J]. NEUROLOGY, 2018, 90
  • [3] Real-world assessment of relapse in patients with multiple sclerosis newly initiating scIFNβ1a compared with oral disease-modifying drugs
    Bowen, J.
    Kozma, C. M.
    Grosso, M.
    Taha, K.
    Phillips, A. L.
    [J]. MULTIPLE SCLEROSIS JOURNAL, 2017, 23 : 665 - 665
  • [4] Treatment Patterns Among Patients With Multiple Sclerosis Newly Initiating Disease-Modifying Therapy
    Freeman, Leorah
    Mehta, Rina
    Tian, Marc
    Pelletier, Corey
    [J]. NEUROLOGY, 2020, 94 (15)
  • [5] An evaluation of adherence in patients with multiple sclerosis newly initiating treatment with a self-injectable or an oral disease-modifying drug
    Munsell, Michael
    Frean, Molly
    Menzin, Joseph
    Phillips, Amy L.
    [J]. PATIENT PREFERENCE AND ADHERENCE, 2017, 11 : 55 - 62
  • [6] Time to First Treatment with Disease-Modifying Drugs in Newly Diagnosed Patients with Multiple Sclerosis
    Meletiche, Dennis M.
    Kozma, Chris
    Dickson, Michael
    [J]. NEUROLOGY, 2009, 72 (11) : A315 - A315
  • [7] PREDICTORS OF NON-ADHERENCE AMONG PATIENTS WITH MULTIPLE SCLEROSIS NEWLY INITIATING ONCE- OR TWICE-DAILY ORAL DISEASE-MODIFYING DRUGS
    Nicholas, J.
    Edwards, N. C.
    Edwards, R. A.
    Dellarole, A.
    Manca, L.
    Harlow, D. E.
    Phillips, A.
    [J]. VALUE IN HEALTH, 2019, 22 : S287 - S287
  • [8] Suboptimal Treatment Outcomes In Employees With Multiple Sclerosis Initiating Disease-modifying Drugs
    Hersh, C. M.
    Brook, R. A.
    Rohrbacker, N. J.
    Beren, I. A.
    Lebson, L.
    Henke, C.
    Phillips, A. L.
    [J]. MULTIPLE SCLEROSIS JOURNAL, 2020, 26 (1_SUPPL) : 35 - 35
  • [9] An evaluation of adherence between patients with multiple sclerosis newly initiating treatment with a self-injectable or an oral disease-modifying drug
    Phillips, A. L.
    Frean, M.
    Locklear, J. C.
    Menzin, J.
    [J]. MULTIPLE SCLEROSIS JOURNAL, 2015, 21 : 603 - 603
  • [10] Utilization Patterns of Oral Disease-Modifying Drugs in Commercially Insured Patients with Multiple Sclerosis
    Desai, Rishi J.
    Mahesri, Mufaddal
    Gagne, Joshua J.
    Hurley, Eimir
    Tong, Angela
    Chitnis, Tanuja
    Minden, Sarah
    Spettell, Claire M.
    Matlin, Olga S.
    Shrank, William H.
    Choudhry, Niteesh K.
    [J]. JOURNAL OF MANAGED CARE & SPECIALTY PHARMACY, 2019, 25 (01): : 113 - 121
12345